Biotech Startups

Lumencor develops photonics solutions and LED lighting technologies. The company serves research, medical, and industrial markets with specialized light sources.

1 investor

Lumi, developed by Reach Industries, builds technology to make scientists and laboratories more efficient in tackling research challenges. It serves the life sciences sector by automating routine lab tasks so scientists can focus on problem solving.

1 investor

1 investor

Lumos Diagnostics develops rapid point-of-care diagnostic tests and digital reader platforms for healthcare professionals, targeting infectious and inflammatory diseases. The company offers both customized assay development services and proprietary branded diagnostic solutions.

1 investor

Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency. It also pursues partnerships to in-license or acquire additional rare disease therapeutic candidates for development and commercialization.

1 investor

LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.

1 investor

Lunaphore provides spatial biology technology and solutions that enable researchers to integrate spatial analysis into laboratory workflows. The company offers a scalable, precision platform designed to make spatial biology research accessible and mainstream across diverse lab environments.

1 investor

1 investor

Luvi develops on-farm fermentation systems that stabilize surplus crops and agricultural sidestreams (such as coffee cherry pulp) into shelf-stable functional ingredients for food and beverage brands. Its first product, Luma, is a fermented Cascara extract rich in polyphenols, natural caffeine, and prebiotic fiber for wellness drinks.

1 investor

Lux Bio develops non-electric, non-toxic lighting products powered by proprietary bioluminescent enzymes, including a water-activated light stick (Lux Light) and a battery-free room-illuminating system (Lux Conduit). Its products are compostable and marketed to commercial, industrial, defense, and consumer users.

1 investor

LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.

1 investor

Lync Bio develops fourth-generation SMART ADC (antibody-drug conjugate) technology for oncology, leveraging proprietary dual-target conjugate design and payload engineering to improve tumor coverage, cellular response, and manufacturability.

1 investor

Lynd Clinical operates a network of clinical research sites in underserved rural and community markets, using technology and local partnerships to expand patient access to clinical trials. The company combines on-the-ground site development with AI-enabled infrastructure to make research populations more representative and accessible to pharmaceutical sponsors.

1 investor

LynxBio (Lynx Biosciences) is a biotech company developing immuno-oncology and immunology therapies using a proprietary patient-based ex vivo disease biology platform combined with a multiomics approach for drug discovery. It partners with biopharmaceutical and technology companies to identify therapeutic candidates while advancing its own internal pipeline.

1 investor

Lyra Therapeutics develops biocompatible mesh scaffolds for sustained drug delivery to the sinonasal passages, targeting treatment of chronic rhinosinusitis. The company's proprietary platform uses bioabsorbable polymers and engineered matrices to deliver medication over up to six months with a single administration.

1 investor

Lyrica is a pharmaceutical product used to manage fibromyalgia, a chronic condition characterized by widespread pain and fatigue. The page provides patient education about fibromyalgia symptoms and treatment options including medication, self-care, and exercise.

1 investor

Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.

1 investor

M20 Genomics develops single-cell and spatial transcriptome sequencing technologies for life science research, drug discovery, and disease diagnosis applications. The company offers proprietary VITA and NATA product lines based on its M20 Seq and M20 Spatial technologies.

1 investor

M2i is a French industrial group specializing in complex molecules and pheromone-based biocontrol products used to protect plants and crops as an alternative to conventional chemical pesticides. It also develops and manufactures active ingredients and intermediates for organic chemistry and life sciences, serving conventional and organic agriculture.

1 investor

A biotech company developing gene therapy treatments for neurodegenerative diseases. The company is led by a founder with extensive clinical and regulatory experience in cell and gene therapy, supported by advisors and board members with deep expertise in neurosurgery, clinical neuroscience, and gene therapy development.

1 investor

MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.

1 investor

Macomics is a drug discovery company developing therapies that target macrophage activity for diseases with limited or ineffective treatment options. It operates in the biotechnology and therapeutics sector.

1 investor

Macro Biologics develops biotherapeutic products based on amino acid polymer technology for applications in therapeutics and diagnostics. The company serves the biopharmaceutical and medical device sectors.

1 investor

Macrocarbon cultivates seaweed species and processes them into sustainable products for industrial applications across multiple sectors. The company leverages marine science expertise to develop drop-in solutions from macroalgae, particularly Sargassum, to support a transition to a blue bioeconomy.

1 investor